

Vehicle
Compound 1 (50 mg/kg)
Paclitaxel (7.5 mg/kg)
Compound 1 (50 mg/kg) + Paclitaxel (7.5 mg/kg)
Average Tumor Volume (mm3)
2500
2000
1500
1000
500
0
11
14
17
20
23
26
29
32
Days After Tumor Implantation
i.v. Dosing (1X/Week): ▲

FIG. 1



Change in body weight (%)
20
15
10
5
0
-5
-10
-15
-20
12
15
18
21
24
27
30
Days After Tumor Implantation
i.v. Dosing (1X/Week): ▲
Vehicle
Paclitaxel (7.5 mg/kg)
Compound 1 (50 mg/kg)
Paclitaxel (7.5 mg/kg) + Compound 1 (50 mg/kg)

FIG. 2



Paclitaxel (10 mg/kg)
Paclitaxel (10 mg/kg) + Compound 1 (50 mg/kg)
Time (h)
0
5
10
15
20
25
100
10
1
0.1
0.01
0.001
Paclitaxel Plasma Concentration (μM)

FIG. 3



Compound 1 Plasma Concentration (μM)
1000
100
10
1
0.1
0.01
0.001
0
5
10
15
20
25
Time (h)
Compound 1 (50 mg/kg)
Compound 1 (50 mg/kg) + Paclitaxel (10 mg/kg)

FIG. 4



% Viability
100
90
80
70
60
50
40
30
20
10
0
0.001
0.01
0.1
1
Compound 1 (μM)
% Viability
100
90
80
70
60
50
40
30
20
10
0
0.01
0.1
1
Paclitaxel (μM)

FIG. 5



6 nM Pac
3 nM Pac
1.5 nM Pac
0.8 nM Pac
Cmpd 1 alone
Fraction affected
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
12 nM
6 nM
3 nM
1.5 nM
Paclitaxel alone
Compound 1 (nM)

FIG. 6



Paclitaxel (5 nM)
Cmpd 1
Combo
Fraction Affected
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
15nM
10nM
7.5nM
5nM
[Compound 1]

FIG. 7





Fraction Affected (H1975 cells)
70%
60%
50%
40%
30%
20%
10%
0%
Cmpd 1
10.7 nM
8.9 nM
7.4 nM
Paclitaxel
3.0 nM
2.5 nM
2.0 nM
Cmpd 1 (10.7nM)
Cmpd 1 (8.9nM)
Paclitaxel (3.0nM)
Cmpd 1 (7.4nM)
Cmpd 1 (10.7nM)
Cmpd 1 (8.9nM)
Paclitaxel (2.5nM)
Cmpd 1 (7.4nM)
Cmpd 1 (10.7nM)
Cmpd 1 (8.9nM)
Paclitaxel (2.0nM)
Cmpd 1 (7.4nM)

FIG. 8




Compound 1 (nM)	Docetaxel (nM)	Fa	CI	
2.51	0.26	0.41	0.99	Nearly additive
4.01	0.26	0.45	0.64	Synergism
6.42	0.26	0.48	0.46	Synergism
2.51	0.41	0.47	0.65	Synergism
4.01	0.41	0.52	0.31	Synergism
6.42	0.41	0.52	0.36	Synergism
2.51	0.66	0.51	0.56	Synergism
4.01	0.66	0.55	0.33	Synergism
6.42	0.66	0.58	0.23	Strong synergism

FIG. 9b




Compound 1 (nM)	Paclitaxel (nM)	Fa	CI	
2.51	0.69	0.39	0.59	Synergism
4.01	0.69	0.46	0.33	Synergism
6.42	0.69	0.50	0.27	Strong synergism
2.51	1.11	0.44	0.51	Synergism
4.01	1.11	0.49	0.35	Synergism
6.42	1.11	0.51	0.33	Synergism
2.51	1.78	0.48	0.57	Synergism
4.01	1.78	0.51	0.45	Synergism
6.42	1.78	0.56	0.29	Strong synergism

FIG. 9a



Compound 1 (nM)	Paclitaxel (nM)	Fa	CI	
6.25	4.97	0.55	0.34	Synergism
10.00	4.97	0.59	0.33	Synergism
16.00	4.97	0.62	0.37	Synergism
6.25	7.95	0.61	0.23	Strong synergism
10.00	7.95	0.63	0.26	Strong synergism
16.00	7.95	0.64	0.32	Synergism
6.25	12.73	0.63	0.23	Strong synergism
10.00	12.73	0.63	0.31	Synergism
16.00	12.73	0.65	0.32	Synergism

FIG. 10A



Compound 1 (nM)	Docetaxel (nM)	Fa	CI	
6.25	2.82	0.66	0.12	Strong synergism
10.00	2.82	0.68	0.14	Strong synergism
16.00	2.82	0.65	0.29	Strong synergism
6.25	4.50	0.65	0.17	Strong synergism
10.00	4.50	0.68	0.14	Strong synergism
16.00	4.50	0.66	0.27	Strong synergism
6.25	7.21	0.71	0.09	Very strong synergism
10.00	7.21	0.69	0.16	Strong synergism
16.00	7.21	0.68	0.23	Strong synergism

FIG. 10B

Compound 1 (nM)	Docetaxel (nM)	Fa	CI	
36.67	0.35	0.67	1.14	Slight antagonism
55.00	0.35	0.82	1.00	Nearly additive
36.67	0.52	0.79	0.94	Nearly additive
55.00	0.52	0.92	0.68	Synergism
36.67	0.79	0.87	0.81	Moderate synergism
55.00	0.79	0.96	0.52	Synergism
36.67	1.18	0.92	0.73	Moderate synergism
55.00	1.18	0.95	0.68	Synergism




FIG. 11



Vehicle
Compound 1 (75mg/kg, 1X/Wk)
Docetaxel (4mg/kg, 1X/Wk)
Compound 1 (75 mg/kg)+Docetaxel (4 mg/kg)
Average Tumor Volume (mm3)
600
500
400
300
200
100
0
12
15
18
21
24
27
30
33
36
39
42
Days After Tumor Implantation
i.v. Dosing (1X/Week): ▲
100
46
26
0

FIG. 12